Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0
|
作者：
Grunwald, Viktor [1 ,2 ]
Powles, Thomas [3 ,4 ]
Eto, Masatoshi [5 ]
Kopyltsov, Evgeny [6 ]
Rha, Sun Young [7 ]
Porta, Camillo [8 ]
Motzer, Robert [9 ]
Hutson, Thomas E. [10 ]
Mendez-Vidal, Maria Jose [11 ]
Hong, Sung-Hoo [12 ]
Winquist, Eric [13 ]
Goh, Jeffrey C. [14 ,15 ]
Maroto, Pablo [16 ]
Buchler, Tomas [17 ,18 ]
Takagi, Toshio [19 ]
Burgents, Joseph E. [20 ]
Perini, Rodolfo [21 ]
He, Cixin [22 ]
Okpara, Chinyere E. [23 ]
McKenzie, Jodi [24 ]
Choueiri, Toni K. [25 ]
机构：
[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany
[2] Univ Hosp Essen, Clin Urol, Essen, Germany
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] Queen Mary Univ London, Royal Free Hosp, London, England
[5] Kyushu Univ, Dept Urol, Fukuoka, Japan
[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia
[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy
[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[10] Texas Oncol, Med Oncol, Dallas, TX USA
[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain
[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea
[13] Univ Western Ontario, Dept Oncol, London, ON, Canada
[14] ICON Res, South Brisbane, Qld, Australia
[15] Univ Queensland, St Lucia, Qld, Australia
[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic
[18] Thomayer Univ Hosp, Prague, Czech Republic
[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA
[21] Merck & Co Inc, Clin Res, Rahway, NJ USA
[22] Eisai Inc, Biostat, Nutley, NJ USA
[23] Eisai Ltd, Clin Res, Hatfield, England
[24] Eisai Inc, Clin Res, Nutley, NJ USA
[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词：
renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;
D O I：
10.3389/fonc.2023.1343027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Grunwald, Viktor
    Powles, Thomas
    Eto, Masatoshi
    Kopyltsov, Evgeny
    Rha, Sun Young
    Porta, Camillo
    Motzer, Robert
    Hutson, Thomas E.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Winquist, Eric
    Goh, Jeffrey C.
    Maroto, Pablo
    Buchler, Tomas
    Takagi, Toshio
    Burgents, Joseph E.
    Perini, Rodolfo
    He, Cixin
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [2] Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
    Gruenwald, V.
    Powles, T.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C.
    Motzer, R.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Winquist, E.
    Goh, J. C.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Burgents, J. E.
    Perini, R.
    He, C.
    Okpara, C. E.
    McKenzie, J.
    Choueiri, T. K.
    ONKOUROLOGIYA, 2024, 20 (01): : 24 - 35
  • [3] Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study
    Eto, Masatoshi
    Takagi, Toshio
    Kimura, Go
    Fukasawa, Satoshi
    Tamada, Satoshi
    Miura, Yuji
    Oya, Mototsugu
    Sassa, Naoto
    Anai, Satoshi
    Nozawa, Masahiro
    Sakai, Hideki
    Perini, Rodolfo
    Yusa, Wataru
    Ikezawa, Hiroki
    Narita, Tomoyuki
    Tomita, Yoshihiko
    CANCER MEDICINE, 2023, 12 (06): : 6902 - 6912
  • [4] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [5] Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomized, phase 3 study
    Motzer, R.
    Porta, C.
    Alekseev, B.
    Rha, S. Y.
    Choueiri, T. K.
    Mendez-Vidal, M. J.
    Hong, S. H.
    Kapoor, A.
    Goh, J. C.
    Eto, M.
    Bennett, L.
    Wang, J.
    Pan, J. J.
    Saretsky, T. L.
    Perini, R. F.
    He, C. S.
    Mody, K.
    Cella, D.
    ONKOUROLOGIYA, 2022, 18 (02): : 39 - 57
  • [6] Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study
    Motzer, Robert J.
    Choueiri, Toni K.
    Hutson, Thomas
    Rha, Sun Young
    Puente, Javier
    Lalani, Aly-Khan A.
    Winquist, Eric
    Eto, Masatoshi
    Basappa, Naveen S.
    Tannir, Nizar M.
    Vaishampayan, Ulka
    Bjarnason, Georg A.
    Oudard, Stephane
    Gruenwald, Viktor
    Burgents, Joseph
    Xie, Ran
    McKenzie, Jodi
    Powles, Thomas
    EUROPEAN UROLOGY, 2024, 86 (01) : 4 - 9
  • [7] Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
    Grunwald, Viktor
    Powles, Thomas
    Kopyltsov, Evgeny
    Kozlov, Vadim
    Alonso-Gordoa, Teresa
    Eto, Masatoshi
    Hutson, Thomas
    Motzer, Robert
    Winquist, Eric
    Maroto, Pablo
    Keam, Bhumsuk
    Procopio, Giuseppe
    Wong, Shirley
    Melichar, Bohuslav
    Rolland, Frederic
    Oya, Mototsugu
    Rodriguez-Lopez, Karla
    Saito, Kenichi
    McKenzie, Jodi
    Porta, Camillo
    EUROPEAN UROLOGY ONCOLOGY, 2023, 6 (04): : 437 - 446
  • [8] Survival by depth of response and efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study
    Gruenwald, V.
    Powles, T.
    Kopyltsov, E.
    Kozlov, V.
    Alonso-Gordoa, T.
    Eto, M.
    Hutson, T.
    Motzer, R.
    Winquist, E.
    Maroto, P.
    Keam, B.
    Procopio, G.
    Wong, S.
    Melichar, B.
    Rolland, F.
    Oya, M.
    Rodriguez-Lopez, K.
    Saito, K.
    McKenzie, J.
    Porta, C.
    ONKOUROLOGIYA, 2023, 19 (04): : 32 - 43
  • [9] Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Motzer, R. J.
    Porta, C.
    Eto, M.
    Hutson, T. E.
    Rha, S. Y.
    Merchan, J. R.
    Winquist, E.
    Gurney, H.
    Gruenwald, V.
    George, S.
    Markensohn, J.
    Burgents, J. E.
    Cristescu, R.
    Sachdev, P.
    Narita, Y.
    Huang, J.
    Zhao, Z.
    Okpara, C. E.
    Minoshima, Y.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2025, 36 (04) : 375 - 386
  • [10] Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial
    Rha, Sun Young
    Choueiri, Toni K.
    Matveev, Vsevolod B.
    Alyasova, Anna
    Hong, Sung-Hoo
    Gordoa, Teresa Alonso
    Gurney, Howard
    Bjarnason, Georg A.
    Buchler, Tomas
    Pedrazzoli, Paolo
    Takagi, Toshio
    Park, Se Hoon
    Lee, Jae Lyun
    Perini, Rodolfo F.
    He, Cixin S. S.
    McKenzie, Jodi A.
    Eto, Masatoshi
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (06) : 1241 - 1250
12345